1 / 14

Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota

Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota. Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction Cancer: Targeting HER2. Median OS Increased to > 1 Year With Trastuzumab-Based Treatment. BSC (1). FAMTX (2). C+S1 (3). CF (4).

vornelas
Télécharger la présentation

Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Axel Grothey, MDProfessor of OncologyMayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction Cancer: Targeting HER2

  2. Median OS Increased to > 1 Year With Trastuzumab-Based Treatment BSC (1) FAMTX (2) C+S1 (3) CF (4) IF (5) EOF (6) DCF (4) ECF (6) ECX (6) XP (7) EOX (6) Trastuzumab + XP/FP (8) HER2 IHC 2+/FISH+ and IHC 3+ 0 5 10 15 Median OS in patients with advanced gastric cancer (months) 1. Murad AM et al. Cancer. 1993;72:37-41. 2. Vanhoefer U et al. J Clin Oncol. 2000;18:2648-2657. 3. Ajani JA et al. J Clin Oncol. 2009; 27(S15):Abstract 4511. 4. Van Cutsem E et al. J Clin Oncol. 2006;24:4991-4997. 5. Dank M et al. J Clin Oncol. 2005;23[Suppl 16S]:4003. 6. Cunningham et al. N Engl J Med. 2008;358:36-46. 7. Kang YK et al. Ann Oncol. 2009;20:666−673. 8. Van Cutsem E et al. J Clin Oncol. 2009;27[Suppl15S]:Abstract 4509.

  3. Primary endpoint: OS Secondary endpoints: PFS, TTP, ORR, clinical benefit rate, duration of response, safety, quality of life, pain intensity, analgesic consumption ToGA Trial Design Capecitabineor 5-FU + cisplatin (XP/FP) (n = 290) HER2-positivelocally advanced or recurrent and/or metastatic GC (n = 584)* 3807 patients screened; 810 HER2-positive R Capecitabineor 5-FU + cisplatin (XP/FP) + trastuzumab (n = 294) *594 patients recruited (10 patients did not receive study drug and were excluded from analyses)5-FU = 5-fluorouracil; GC = gastric cancer; HER2 = human epidermal growth factor receptor 2; ORR = overall response rate; OS = overall survival; R = randomised; TTP = time to progression; XP/FP = capecitabine/5-FU + cisplatin Van Cutsem E et al. J Clin Oncol. 2009; 27(Suppl 15S): Abstract 4509.

  4. Trastuzumab + XP/FP Improves OS vs XP/FP Alone 1.0 0.9 0.8 0.7 0.6 0.5 Probability 0.4 0.3 0.2 11.1 13.8 0.1 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 Time (mo) No. at risk 294 290 277 266 246 223 209 185 173 143 147 117 113 90 90 64 71 47 56 32 43 24 30 16 21 14 13 7 12 6 6 5 4 0 1 0 0 0 CI = confidence interval; HR = hazard ratio Van Cutsem E et al. J Clin Oncol. 2009; 27(Suppl 15S): Abstract 4509.

  5. ToGA: OS in IHC 2+/FISH+ and IHC 3+ Subgroup (Exploratory Analysis) 1.0 0.9 0.8 0.7 0.6 0.5 Probability 0.4 0.3 0.2 0.1 11.8 16.0 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 Time (mo) No. at risk 218 198 196 170 170 141 142 112 12296 100 75 84 53 65 39 51 28 39 20 28 13 20 11 12 4 11 3 5 3 4 0 1 0 0 0 228 218 FISH = fluorescence in situ hybridization; IHC = immunohistochemistry Van Cutsem E et al. J Clin Oncol. 2009; 27(Suppl 15S):Abstract 4509.

  6. Trastuzumab Does Not Impact Overall or Cardiac Safety AEs = adverse events Van Cutsem E et al. J Clin Oncol. 2009; 27(Suppl15S):Abstract 4509.

  7. Patient History and Presentation of Disease Personal history: 64-year-old male accountant from Virginia Healthy, good performance status Disease presentation: December 2009 Developed dysphagia Esophagogastroduodenoscopy revealed mass at the gastroesophageal junction Biopsies confirmed adenocarcinoma CT scan showed multiple intrahepatic metastases Patient consulted Mayo Clinic in January 2010; plans to moveto Minnesota to be closer to his children in the Twin Cities

  8. CT Scans Before Treatment (January 19, 2010) Imaging studies property of Axel Grothey, MD.

  9. Treatment Identified goals of therapy: extend life and maintain quality of life as long as possible Started EOX as palliative therapy Initiated HER2 testing of outside (liver) biopsy Tumor found to be HER2 IHC 3+ according to Hofmann criteria1 From Cycle 2 on, trastuzumab utilized instead of epirubicin (“HOX” regimen) Excellent tolerability of therapy CT scans every 3 cycles (9 weeks), no treatment delays EOX = epirubicin, oxaliplatin and capecitabine1. Hofmann M et al. Histopathology. 2008;52:797–805.

  10. Mar 23, 2010 Jun 25, 2010 CT Scans Before and After Treatment Jan 19, 2010 Imaging studies property of Axel Grothey, MD.

  11. Mar 23, 2010 Jun 25, 2010 CT Scans Before and After Treatment Jan 19, 2010 Imaging studies property of Axel Grothey, MD.

  12. Clinical Course Most recent appointment on June 28, 2010 Patient doing very well No dysphagia Feels energetic Only relevant side effect at this point is grade 2 sensory neurotoxicity from oxaliplatin (780 mg/m2 cumulative dose) Plan to continue trastuzumab + capecitabine, but omit oxaliplatin from therapy Continue assessment every 9 weeks

  13. Gastric Cancer vs Gastroesophageal Junction Cancer • Incidence of gastric cancer declining; incidence of gastroesophageal junction cancer increasing • HER2 overexpression: • 1820% in adenocarcinoma of stomach • ~30% in gastroesophageal junction cancer • Given increasing incidence of gastroesophageal junction cancer and higher percentage of patients with HER2 overexpression, trastuzumab becomes even more important

  14. Conclusions • Trastuzumab is the first targeted therapy to show survival benefit in gastric and gastroesophageal junction cancers • Survival benefit greatest in patients with high levels of HER2 expression (median OS: 16 months) • All patients with gastric and gastroesophageal junction cancers should be tested for HER2 • Trastuzumab plus chemotherapy is well tolerated • Trastuzumab plus chemotherapy is setting a new standard of care in patients with HER2-positive metastatic gastric cancer

More Related